Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) version 1.1

BACKGROUND: Immune checkpoint inhibitors (ICIs) treatment is a breakthrough in managing metastatic solid tumours, but its use is associated with a high financial burden for public health care systems. Validated tools such as the European Society for Medical Oncology-Magnitude of Clinical Benefit Sca...

Descripción completa

Detalles Bibliográficos
Autores principales: Pichler, M., Steyrer, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253953/
https://www.ncbi.nlm.nih.gov/pubmed/34175674
http://dx.doi.org/10.1016/j.esmoop.2021.100198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253953/
https://www.ncbi.nlm.nih.gov/pubmed/34175674
http://dx.doi.org/10.1016/j.esmoop.2021.100198

Ejemplares similares